Effects of gamma-linolenic and eicosapentaenoic acids on blood pressure in SHR.
1. The present study was performed to determine whether chronic treatments with gamma linolenic acid (n-6, GLA) or eicosapentaenoic acid (n-3, EPA) would alter serum and red blood cell (RBC) unsaturated fatty acid composition, and to determine whether these treatments would affect blood pressure (BP), serum lipid metabolism and the development of atherosclerosis in spontaneously hypertensive rats (SHR). 2. To compare the effects on atherosclerosis, some SHR were denuded of aortic endothelium so that the development of atherosclerosis would be accelerated. Olive oil (control), GLA or EPA (low dose: 5 mg/day per rat, high dose: 50 mg/day per kg, respectively) was administered intraperitoneally for 6 weeks in SHR. 3. GLA treatments increased GLA and its metabolite, dihomo-GLA, levels in serum but not in RBC, while EPA treatments increased EPA level both in serum and in RBC. 4. The BP of control SHR was further elevated. EPA significantly reduced this elevation of systolic, mean and diastolic pressure within the first week and thereafter, whereas GLA did not affect BP elevation. Neither heart rate or bodyweight gain was affected by these treatments. 5. Serum total cholesterol (TC), triglyceride (TG), and glucose (G) levels and the development of atherosclerosis were unaffected by either GLA or EPA treatment. 6. In summary, chronic EPA but not GLA treatment slightly reduced BP elevation in SHR. Although chronic GLA or EPA treatment increased the respective serum level, these treatments unaltered serum TC, TG and G levels, and could not prevent the development of aortic atherosclerosis in SHR.
Sasaki
S
S
Second Department of Medicine, Kyoto Prefectural University of Medicine, Japan.
Nakamura
K
K
Uchida
A
A
Fujita
H
H
Itoh
H
H
Nakata
T
T
Takeda
K
K
Nakagawa
M
M
D000818:Animals; D001161:Arteriosclerosis / Q000097:blood / Q000517:prevention & control; D001794:Blood Pressure / Q000187:drug effects*; D015118:Eicosapentaenoic Acid / Q000097:blood / Q000494:pharmacology*; D004912:Erythrocytes / Q000187:drug effects / Q000378:metabolism; D006973:Hypertension / Q000503:physiopathology*; D008055:Lipids / Q000097:blood; D008297:Male; D051381:Rats; D011918:Rats, Inbred SHR; D017965:gamma-Linolenic Acid / Q000097:blood / Q000494:pharmacology*
D008055:Lipids; D017965:gamma-Linolenic Acid; D015118:Eicosapentaenoic Acid